Perfusion Abnormalities in Hypertrophic Cardiomyopathy

Running, not enrolling

Conditions studied: Hypertrophic Cardiomyopathy (HCM)

In brief

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Key facts

Study ID

NCT06599229

Run by

University of Virginia

People needed

30

Starts

2025-01-02

Expected to finish

2026-12-01

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of hypertrophic cardiomyopathy
• Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

You may not qualify if…

• Pregnancy
• Lactation
• Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
• Serious AE to regadenoson
• Hypotension
• Serious bradycardia not addressed by pacemaker
• Moderate or greater reactive airways disease

Where it is running

• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.